Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma

被引:1
|
作者
Shi, Diana D. [1 ,2 ]
Lee, Joyce H. [3 ]
Wang, Adam C. [3 ]
Khanal, Januka [3 ]
Gao, Wenhua [3 ]
Kaelin Jr, William G. [3 ,4 ]
Mcbrayer, Samuel K. [2 ,5 ,6 ]
机构
[1] Harvard Med Sch, Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02115 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Childrens Med Ctr Res Inst, Dallas, TX 75390 USA
[3] Harvard Med Sch, Dana Farber Canc Inst, Brigham & Womens Hosp, Dept Med Oncol, Boston, MA USA
[4] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA
[5] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dept Pediat, Dallas, TX 75390 USA
[6] Univ Texas Southwestern Med Ctr Dallas, Harold C Simmons Comprehens Canc Ctr, Dallas, TX 75235 USA
来源
STAR PROTOCOLS | 2023年 / 4卷 / 02期
关键词
Cancer; Model Organisms; Neuroscience;
D O I
10.1016/j.xpro.2023.102281
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Lower-grade gliomas exhibit a high prevalence of isocitrate dehydrogenase 1 (IDH1) mutations, but faithful models for studying these tumors are lacking. Here, we present a protocol to establish a genetically engineered mouse (GEM) model of grade 3 astrocytoma driven by the Idh1R132H oncogene. We describe steps for breeding compound transgenic mice and intracranially delivering adeno-associated virus particles, followed by post-surgical surveillance via magnetic resonance imaging. This protocol enables the generation and use of a GEM to study lower-grade IDH-mutant gliomas.For complete details on the use and execution of this protocol, please refer to Shi et al. (2022).1
引用
收藏
页数:17
相关论文
共 50 条
  • [31] Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
    Uson Junior, Pedro Luiz Serrano
    Borad, Mitesh J.
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 1025 - 1031
  • [32] Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses
    Wen Cheng
    Xiufang Ren
    Chuanbao Zhang
    Jinquan Cai
    Sheng Han
    Anhua Wu
    Molecular Neurobiology, 2017, 54 : 5996 - 6005
  • [33] Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses
    Cheng, Wen
    Ren, Xiufang
    Zhang, Chuanbao
    Cai, Jinquan
    Han, Sheng
    Wu, Anhua
    MOLECULAR NEUROBIOLOGY, 2017, 54 (08) : 5996 - 6005
  • [34] PARACRINE IMPAIRMENT OF ANTITUMOR T CELL IMMUNITY BY IDH1-MUTANT GLIOMAS
    Bunse, L.
    Bunse, T.
    Pusch, S.
    Sahm, F.
    Sanghvi, K.
    Berghoff, A.
    Steadman, M.
    Niemeyer, B.
    Wick, W.
    Platten, M.
    NEURO-ONCOLOGY, 2016, 18 : 4 - 5
  • [35] CONNEXIN 43 BLOCKADE INHIBITS PROLIFERATION IN IDH1-MUTANT GLIOMA CELLS
    Melamed, Lisa
    Lee, Christine
    Nagashima, Hiroaki
    Miller, Julie
    Wakimoto, Hiroaki
    Cahill, Daniel
    NEURO-ONCOLOGY, 2020, 22 : 221 - 221
  • [36] DNMT3A co-mutation in an IDH1-mutant glioblastoma
    Fomchenko, Elena, I
    Erson-Omay, E. Zeynep
    Zhao, Amy
    Bindra, Ranjit S.
    Huttner, Anita
    Fulbright, Robert K.
    Moliterno, Jennifer
    COLD SPRING HARBOR MOLECULAR CASE STUDIES, 2019, 5 (04):
  • [37] Development and validation of a novel IDH1-mutant astrocyte cell line as a model for high-grade gliomas
    Robinson, Nathaniel D.
    Purshouse, Karin R.
    Fons, Nathan R.
    Breuer, Gregory A.
    Pusch, Stefan
    von Deimling, Andreas
    Sundaram, Ranjini K.
    Bindra, Ranjit S.
    CANCER RESEARCH, 2016, 76
  • [38] Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
    Cho, Nicholas S.
    Hagiwara, Akifumi
    Eldred, Blaine S. C.
    Raymond, Catalina
    Wang, Chencai
    Sanvito, Francesco
    Lai, Albert
    Nghiemphu, Phioanh
    Salamon, Noriko
    Steelman, Lori
    Hassan, Islam
    Cloughesy, Timothy F.
    Ellingson, Benjamin M.
    NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
  • [39] ZEB1 expression is increased in IDH1-mutant lower-grade gliomas
    Nesvick, Cody L.
    Zhang, Chao
    Edwards, Nancy A.
    Montgomery, Blake K.
    Lee, Michaela
    Yang, Chunzhang
    Wang, Herui
    Zhu, Dongwang
    Heiss, John D.
    Merrill, Marsha J.
    Ray-Chaudhury, Abhik
    Zhuang, Zhengping
    JOURNAL OF NEURO-ONCOLOGY, 2016, 130 (01) : 111 - 122
  • [40] Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study
    Lowery, Maeve A.
    Burris, Howard A., III
    Janku, Filip
    Shroff, Rachna T.
    Cleary, James M.
    Azad, Nilofer S.
    Goyal, Lipika
    Maher, Elizabeth A.
    Gore, Lia
    Hollebecque, Antoine
    Beeram, Muralidhar
    Trent, Jonathan C.
    Jiang, Liewen
    Fan, Bin
    Aguado-Fraile, Elia
    Choe, Sung
    Bin Wu
    Gliser, Camelia
    Agresta, Samuel, V
    Pandya, Shuchi S.
    Zhu, Andrew X.
    Abou-Alfa, Ghassan K.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2019, 4 (09): : 711 - 720